Pipeline Insights on Nonalcoholic Steatohepatitis Market

PUNE, India, September 12, 2016 /PRNewswire/ --

RnRMarketResearch.com adds "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2016" market research report with comprehensive information on NASH therapeutic development complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects.

Complete report on H2 2016 pipeline review of Non-Alcoholic Steatohepatitis with 94 market data tables and 15 figures, spread across 342 pages is available at http://www.rnrmarketresearch.com/non-alcoholic-steatohepatitis-pipeline-review-h2-2016-market-report.html .

Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. The report also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this Non-Alcoholic Steatohepatitis Pipeline Review, H2 2016 report include Akarna Therapeutics Ltd., AlbireoPharma, Alnylam Pharmaceuticals, Inc., Amunix Operating Inc., Aquinox Pharmaceuticals Inc., Arisaph Pharmaceuticals, Inc., AstraZeneca Plc, BiOrion Technologies B.V., Bird Rock Bio, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Can-Fite BioPharma Ltd., Cardax Pharmaceuticals, Inc., Catabasis Pharmaceuticals, Inc., Cerenis Therapeutics Holding SA, Conatus Pharmaceuticals Inc., Connexios Life Sciences Pvt. Ltd., ,Daiichi Sankyo Company Limited, DURECT Corporation, Dynavax Technologies Corporation, Eli Lilly and Company, Enanta Pharmaceuticals, Inc., Exicure, Inc., Galectin Therapeutics, Inc., Galmed Pharmaceuticals Ltd., Genextra S.p.a., Genfit SA, GenKyoTex S.A., Gilead Sciences, Inc., GRI Bio, Inc., iCo Therapeutics Inc., Immuron Limited, Inventiva, Ionis Pharmaceuticals, Inc., Ixchel Pharma, LLC, Jenrin Discovery, Inc., Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Matinas BioPharma Holdings, Inc., Merck & Co., Inc., Mitochon Pharmaceuticals, Inc., Naia Limited, NGM Biopharmaceuticals, Inc., Nimbus Therapeutics, LLC, Nippon Chemiphar Co., Ltd, Nitto Denko Corporation, Novartis AG, NovaTarg Therapeutics, Inc, Nuevolution AB, Pharmaxis Limited, Promethera Biosciences S.A., ProMetic Life Sciences Inc., Protalix BioTherapeutics, Inc., Saje Pharma, LLC, Shire Plc, Stelic Institute & Co., Inc., Sucampo Pharmaceuticals, Inc., TaiwanJ Pharmaceuticals Co., Ltd., Teva Pharmaceutical Industries Ltd., Therapix Biosciences Ltd, Tobira Therapeutics, Inc., Vascular Biogenics Ltd., Verlyx Pharma Inc., Viking Therapeutics, Inc., Virobay Inc., Zafgen Inc. and Zydus Cadila Healthcare Limited.

Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=674891 .

Drug Profiles mentioned in this research report are (leucine + metformin hydrochloride + sildenafil citrate), (leucine + PDE5 Inhibitor), A-4250, AC-261066, AM-0010, AMX-342, Antisense Oligonucleotides for Non-Alcoholic Steatohepatitis, AQX-1125, Aramchol, ARI-3037MO, AZD-4076, bertilimumab, BMS-986036, BMS-986171, BOT-191, CAT-2000 Series, CAT-2054, CDX-085, cenicriviroc mesylate, CER-209, CF-102, CNX-014, CNX-023, CNX-024, CNX-025, DRX-065, DUR-928, DV-1179, EDP-305, elafibranor, emricasan, etanercept biosimilar, evogliptin, GKT-831, GRI-0621, GRMD-02, GS-9674, HepaStem, IMM-124E, IONIS-DGAT2Rx, IVA-337, IXC-303, IXC-305, JD-5037, JKB-119, JKB-121, linagliptin, LJN-452, MAT-8800, MGL-3196, MGL-3745, MP-301, MSDC-0602, MT-2002, NC-101, NC-2400, ND-630, ND-654, ND-L02s0201, NDI-010976, NGM-282, NGM-313, NGM-386, NGM-395, NP-201 Program, obeticholic acid, PBI-4050, pentamidine isethionate, PXS-4728A, PXS-5033A, PZ-235, remogliflozin etabonate, RNAi Oligonucleotides for NASH, Cardiovascular and Metabolic Disorders, RTU-1096, RYI-018, saroglitazar, selonsertib, selonsertib + simtuzumab, simtuzumab, Small Molecule for Non-Alcoholic Steatohepatitis, Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease, Small Molecule to Agonize FXR for NASH and Liver Fibrosis, Small Molecule to Inhibit DGAT-2 for Dyslipidemia and Non-Alcoholic Steatohepatitis, Small Molecule to Inhibit SCD-1 for Non-alcoholic Steatohepatitis, Small Molecules to Activate AMPK for Fatty Liver Disease, Small Molecules to Antagonize Integrin for Non-Alcoholic Steatohepatitis, Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis and Non-Alcoholic Steatohepatitis, Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis, Non-Alcoholic Steatohepatitis, Small Molecules to Inhibit MLK3 for Non-Alcoholic Steatohepatitis, Small Molecules to Inhibit NLRP3 for Liver Cirrhosis and Non-Alcoholic Steatohepatitis, solithromycin, SPL-891.1, SR-9238, STNM-09, TEV-45478, TGFTX-3, tipelukast, TRX-318, VB-201, VB-703, VBY-376, VK-2809, volixibat potassium and ZGN-839.

Explore more reports on Therapeutics .

About Us: 

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com

Connect with Us:  

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed